Home › Funds › AMI ASSET MANAGEMENT CORP › ARQT
AMI ASSET MANAGEMENT CORP position in ARQT
ARCUTIS BIOTHERAPEUTICS INC · Health Care
AMI ASSET MANAGEMENT CORP reported holding 41,505 shares of ARQT (ARCUTIS BIOTHERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$1.1M, representing 0.07% of its reported portfolio and ranking #42 among its reported holdings. AMI ASSET MANAGEMENT CORP has disclosed ARQT holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How AMI ASSET MANAGEMENT CORP's ARQT position evolved
AMI ASSET MANAGEMENT CORP first disclosed a stake in ARQT in Q1 2024 at 345,239 shares (US$3.4M). Across 11 filings, AMI ASSET MANAGEMENT CORP increased the stake 3 time(s), trimmed it 7 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 41,505 shares valued at US$1.1M — an increase of 4,384 shares quarter over quarter.. Notable position changes include a 52% trim in Q2 2024 (shares were roughly flat over the following quarter), a 45% trim in Q2 2025 (shares rose 34% over the following quarter), a 49% trim in Q4 2025 (shares fell 19% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 345.24K | $3.42M | New |
| Q2 2024 | 164.19K | $1.53M | Reduce |
| Q3 2024 | 223.68K | $2.08M | Add |
| Q4 2024 | 215.96K | $3.01M | Reduce |
| Q1 2025 | 208.72K | $3.26M | Reduce |
| Q2 2025 | 113.88K | $1.60M | Reduce |
| Q3 2025 | 96.09K | $1.81M | Reduce |
| Q4 2025 | 49.26K | $1.43M | Reduce |
| Q1 2026 | 50.86K | $1.20M | Add |
| Q2 2026 | 37.12K | $973.31K | Reduce |
| Q3 2026 | 41.51K | $1.10M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ARQT and 13F data
ARQT (ARCUTIS BIOTHERAPEUTICS INC) is a Health Care company. 47 other funds we track also report a position in ARQT — the largest reported positions include MONTANOVA CAPITAL, LLC (US$326.1M), Frazier Life Sciences Management, L.P. (US$258.9M), Rubric Capital Management LP (US$216.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ARQT
- MONTANOVA CAPITAL, LLC 12.44M sh · $326.10M · Q2 2026
- Frazier Life Sciences Management, L.P. 9.87M sh · $258.91M · Q2 2026
- Rubric Capital Management LP 8.27M sh · $216.88M · Q2 2026
- ORBIMED ADVISORS LLC 2.04M sh · $53.54M · Q2 2026
- OBERWEIS ASSET MANAGEMENT INC/ 1.37M sh · $36.00M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 1.27M sh · $33.18M · Q2 2026
- Simplify Asset Management Inc. 865.86K sh · $22.88M · Q3 2026
More on AMI ASSET MANAGEMENT CORP
FAQ
How long has AMI ASSET MANAGEMENT CORP held ARQT?
AMI ASSET MANAGEMENT CORP has disclosed ARQT holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
What is AMI ASSET MANAGEMENT CORP's current position in ARQT?
As of Q3 2026, AMI ASSET MANAGEMENT CORP holds 41.51K shares of ARQT (ARCUTIS BIOTHERAPEUTICS INC), valued at $1.10M, representing 0.07% of its reported portfolio and ranking #42.
Has AMI ASSET MANAGEMENT CORP been buying or selling ARQT?
In the latest 13F filing (Q3 2026), AMI ASSET MANAGEMENT CORP increased its position in ARQT.
Which other funds hold ARQT?
Other major institutional holders of ARQT include MONTANOVA CAPITAL, LLC, Frazier Life Sciences Management, L.P., Rubric Capital Management LP, among 47 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.